Multiplex Bead-Based Immunoassay Validated for Non-Invasive Bladder Cancer Detection
By LabMedica International staff writers Posted on 04 Jan 2021 |
Image: Oncuria is a simple urine test that detects and analyzes multiple tumor protein biomarkers for improved bladder cancer detection (Photo courtesy of Nonagen Bioscience Corporation).
Cancer of the urinary bladder has two unique features: the tumor is continuously immersed in a urine and the tumor is able to shed cells or release tumor associated products (e.g., protein, DNA, RNA) directly into urine, which is easily collected and assessed.
Though urine is largely considered a harsh environment with varying pH and high salt levels, products associated with bladder tumors within the urine have been shown to correlate with their presence within the actual bladder tumor. Promising diagnostic biomarkers included nuclear matrix protein 22 (NMP-22) and bladder tumor antigen (BTA). Unfortunately, these tests suffer from high false-positive rates.
A multidisciplinary team of scientists collaborating with Cedars-Sinai Medical Center (Los Angeles, CA, USA) assessed the analytical performance of a multiplex assay called Oncuria (Nonagen Bioscience Corporation, Los Angeles, CA, USA) to quantify protein biomarkers towards a bladder cancer associated diagnostic signature in voided urine. The team used Luminex xMAP technology (Luminex Corporation, Austin, TX, USA), to measure the concentrations of 10 urinary analytes: angiogenin, (ANG); apolipoprotein E, (APOE); alpha-1 antitrypsin, (A1AT); carbonic anhydrase 9,(CA9); interleukin 8, (IL8); matrix metallopeptidase 9, (MMP9); matrix metallopeptidase 10, (MMP10); plasminogen activator inhibitor 1, (PAI1); syndecan 1, (SDC1); vascular endothelial growth factor, (VEGF).
The scientists reported that their analytical evaluation demonstrated a) all antigen cross-reactivity was noted to be <1% of the tested concentration, b) minimal detected dose ranged from 0.295 pg/mL in IL8 to 31.1 pg/mL in APOE, c) highly reproducible and accurate noting coefficient of variation (CV) and relative error (RE) values below 15% for all analytes and d) minimal interference. The assay can be completed in less than five hours using as little as 150 μL of voided urine.
The authors concluded that Oncuria is the first multiplex bead-based immunoassay for the non-invasive detection of bladder cancer that has been analytically validated as a tool with the potential to help clinicians manage patients at risk of harboring bladder cancer. They believe that this assay, unlike most urine-based diagnostic assays, is well suited to identify patients who may require additional testing to rule in the presence of a bladder tumor. Implementing the assay clinically is a necessary first step to improve on current diagnostic approaches and to demonstrate the clinical utility of advanced molecular diagnostic testing. The study was published on November 13, 2020 issue of the journal Practical Laboratory Medicine.
Related Links:
Cedars-Sinai Medical Center
Nonagen Bioscience Corporation
Luminex Corporation
Though urine is largely considered a harsh environment with varying pH and high salt levels, products associated with bladder tumors within the urine have been shown to correlate with their presence within the actual bladder tumor. Promising diagnostic biomarkers included nuclear matrix protein 22 (NMP-22) and bladder tumor antigen (BTA). Unfortunately, these tests suffer from high false-positive rates.
A multidisciplinary team of scientists collaborating with Cedars-Sinai Medical Center (Los Angeles, CA, USA) assessed the analytical performance of a multiplex assay called Oncuria (Nonagen Bioscience Corporation, Los Angeles, CA, USA) to quantify protein biomarkers towards a bladder cancer associated diagnostic signature in voided urine. The team used Luminex xMAP technology (Luminex Corporation, Austin, TX, USA), to measure the concentrations of 10 urinary analytes: angiogenin, (ANG); apolipoprotein E, (APOE); alpha-1 antitrypsin, (A1AT); carbonic anhydrase 9,(CA9); interleukin 8, (IL8); matrix metallopeptidase 9, (MMP9); matrix metallopeptidase 10, (MMP10); plasminogen activator inhibitor 1, (PAI1); syndecan 1, (SDC1); vascular endothelial growth factor, (VEGF).
The scientists reported that their analytical evaluation demonstrated a) all antigen cross-reactivity was noted to be <1% of the tested concentration, b) minimal detected dose ranged from 0.295 pg/mL in IL8 to 31.1 pg/mL in APOE, c) highly reproducible and accurate noting coefficient of variation (CV) and relative error (RE) values below 15% for all analytes and d) minimal interference. The assay can be completed in less than five hours using as little as 150 μL of voided urine.
The authors concluded that Oncuria is the first multiplex bead-based immunoassay for the non-invasive detection of bladder cancer that has been analytically validated as a tool with the potential to help clinicians manage patients at risk of harboring bladder cancer. They believe that this assay, unlike most urine-based diagnostic assays, is well suited to identify patients who may require additional testing to rule in the presence of a bladder tumor. Implementing the assay clinically is a necessary first step to improve on current diagnostic approaches and to demonstrate the clinical utility of advanced molecular diagnostic testing. The study was published on November 13, 2020 issue of the journal Practical Laboratory Medicine.
Related Links:
Cedars-Sinai Medical Center
Nonagen Bioscience Corporation
Luminex Corporation
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms